LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
NCT ID: NCT05171491
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
425 participants
OBSERVATIONAL
2022-01-26
2024-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound
NCT01201824
Intra-op vs Pre-op Transbronchial Localization for Small Lung Nodule
NCT03793387
Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules
NCT06825078
Evaluation for Benign and Malignant Pulmonary Ground-glass Nodules Based on MRI Dynamic Contrast Enhanced Imaging
NCT05067023
Respiration Gated Laser Guided CT Lung Nodule Biopsy
NCT01236937
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Indeterminate Lung Nodule
Subjects that present with indeterminate lung nodules at time of biopsy. No intervention outside of standard of care.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Planned biopsy nodule of interest:
1. is solid ≤3 cm; or
2. is nonsolid, ground glass opacity, of any size; or
3. is part solid, where the solid component is no larger than 3cm (maximum diameter).
Exclusion Criteria
2. Current and or prior lung cancer diagnosis within 2 years following intent-to-cure surgery.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LungLife AI
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Donovan, MD
Role: STUDY_DIRECTOR
LungLife AI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Site 04
Los Angeles, California, United States
Clinical Site 05
Bay Pines, Florida, United States
Clinical Site 03
Miami, Florida, United States
Clinical Site 07
Hines, Illinois, United States
Clinical Site 27
Kansas City, Kansas, United States
Clinical Site 12
Wichita, Kansas, United States
Clinical Site 08
Kansas City, Missouri, United States
Clinical Site 18
Reno, Nevada, United States
Clinical Site 01
New York, New York, United States
Clinical Site 25
Columbia, South Carolina, United States
Clinical Site 02
Houston, Texas, United States
Clinical Site 32
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAI-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.